News

Partner companies' news

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022
SAN JOSE, Calif. , April 6, 2022 /PRNewswire/ --  Anixa Biosciences, Inc. [1] (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— April 2022 — 426 views ANIX

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
CELEBRATION, Fla., March 30, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...
Acorn Management Partners, Administrator
— April 2022 — 454 views KMPH

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
SAN JOSE, Calif. , March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1] (NASDAQ: ANIX), a biotechnology company focused on the treatment and...
Acorn Management Partners, Administrator
— April 2022 — 468 views ANIX

KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery a...
Acorn Management Partners, Administrator
— March 2022 — 477 views KMPH

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
CELEBRATION, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company or KemPharm), a specialty pharmaceutical company ...
Acorn Management Partners, Administrator
— March 2022 — 455 views KMPH

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC
SAN JOSE, Calif. , March 17, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1] (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— March 2022 — 488 views ANIX

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), a specialty pharmaceutical company...
Acorn Management Partners, Administrator
— March 2022 — 433 views KMPH

KemPharm to Report Fourth Quarter and Full-Year 2021 Results
CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery a...
Acorn Management Partners, Administrator
— March 2022 — 477 views KMPH

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— February 2022 — 462 views KMPH

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— January 2022 — 529 views ANIX

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focuse...
Acorn Management Partners, Administrator
— January 2022 — 469 views ANIX

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
CELEBRATION, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 446 views KMPH

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 464 views KMPH

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 455 views KMPH

Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 454 views ARTH

KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— January 2022 — 485 views KMPH

Arch Therapeutics Announces Appointment of Guy Fish to the Board
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 539 views ARTH

KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery an...
Acorn Management Partners, Administrator
— December 2021 — 516 views KMPH

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference
SAN JOSE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— December 2021 — 475 views ANIX

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
CELEBRATION, Fla., Dec. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and ...
Acorn Management Partners, Administrator
— December 2021 — 473 views KMPH

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives